Diploma (LON:DPLM) Price Target Raised to GBX 6,800 at Stifel Nicolaus

Diploma (LON:DPLM) had its target price lifted by Stifel Nicolaus from GBX 6,200 to GBX 6,800 in a research report released on Thursday morning, MarketBeat reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Peel Hunt reiterated a “buy” rating and set a GBX 6,150 price target on shares of Diploma in a report on Friday, December 19th. Shore Capital Group reissued a “hold” rating on shares of Diploma in a report on Wednesday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Diploma from GBX 6,000 to GBX 6,200 and gave the company a “buy” rating in a research report on Wednesday, January 14th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 6,350 price objective on shares of Diploma in a research note on Wednesday, November 19th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of GBX 6,023.75.

Diploma Stock Performance

LON:DPLM opened at GBX 5,795 on Thursday. The company has a debt-to-equity ratio of 46.97, a quick ratio of 0.80 and a current ratio of 2.04. Diploma has a fifty-two week low of GBX 3,532 and a fifty-two week high of GBX 6,019.52. The firm has a market cap of £7.77 billion, a PE ratio of 42.21, a price-to-earnings-growth ratio of 2.82 and a beta of 1.03. The business has a 50 day moving average price of GBX 5,456.45 and a 200-day moving average price of GBX 5,423.86.

Insider Activity

In related news, insider Johnny Thomson sold 30,000 shares of Diploma stock in a transaction on Friday, January 16th. The shares were sold at an average price of GBX 5,668, for a total value of £1,700,400. Also, insider Ian El-Mokadem purchased 500 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The stock was bought at an average price of GBX 5,615 per share, for a total transaction of £28,075. Insiders own 1.14% of the company’s stock.

Diploma News Summary

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Diploma upgraded full‑year guidance after a stronger‑than‑expected first half, citing resilient aerospace demand — this is the catalyst that drove the recent rally. Article Title Article Title
• Positive Sentiment: Berenberg raised its price target to GBX 7,500 and moved to a “buy” rating, signaling stronger analyst conviction. Article Title
• Positive Sentiment: Stifel Nicolaus lifted its target to GBX 6,800 and reiterated a “buy” stance, reflecting upgraded earnings assumptions. Article Title
• Positive Sentiment: RBC increased its target to GBX 6,600 and moved to “outperform” after Diploma’s guidance upgrade; coverage note posted to LSE and TickerReport. Article Title Article Title
• Positive Sentiment: Deutsche Bank raised its target to GBX 6,400 and set a “buy” rating, further supporting the upgraded consensus view. Article Title
• Neutral Sentiment: Shore Capital reaffirmed a “hold” rating — a reminder some brokers remain cautious despite upgrades. Article Title Article Title
• Neutral Sentiment: Valuation sits elevated after the rally (P/E ~42, PEG ~2.8) and the stock is near its 1‑year high — this raises the bar for further upside absent continued operational beats.
• Negative Sentiment: Despite the positive fundamentals and multiple target lifts, the stock is pulling back mid‑day on very heavy volume — likely short‑term profit‑taking and consolidation after the recent surge.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.